RNAi Consortium (TRC) Lentiviral shRNA

Product description
The TRC Lentiviral shRNA Library is the result of a collaborative research effort based at the Broad Institute of MIT and Harvard, and included six MIT and Harvard associated research institutions and five international life sciences organizations. The goal of TRC was to create lentiviral shRNA libraries targeting 15,000 human and 15,000 mouse annotated genes with multiple constructs per gene. We have partnered with the TRC to make these shRNA libraries available to researchers worldwide.

Shipping and storage
All constructs are shipped as bacterial cultures of *E. coli* (DH5α) in 2x LB-Lennox broth (low salt) medium with 8% glycerol, 100 μg/mL carbenicillin. Individual constructs are shipped on wet ice and collections are shipped on dry ice in a 96-well plate format. All constructs should be stored at –80 °C. All cultures are checked for growth prior to shipment. To allow any CO₂ that may have dissolved into the medium from the dry ice during shipping to dissipate, please store plates at –80 °C for at least 48 hours before thawing.

Important safety note
Please follow the safety guidelines for use and production of vector-based lentivirus as set by your institution’s biosafety committee.

- For glycerol stocks of *E. coli* containing lentiviral plasmids, BSL1 guidelines should be followed
- For handling and use of lentiviral products to produce lentiviral particles, BSL2 or BSL2+ guidelines should be followed
- For handling and use of lentiviral particle products, BSL2 or BSL2+ guidelines should be followed

Design information
TRC Lentiviral shRNA library design
The shRNA constructs were designed to include a hairpin consisting of a 21 base paired stem (sense and antisense strands) separated by a 6 base loop. Each hairpin sequence was cloned into the lentiviral vector (pLKO.1) and sequence verified. Multiple constructs (4–5) were created per gene to ensure adequate coverage of the target gene. The TRC predicts that 1 or 2 out of the 4–5 constructs offered per gene are expected to give at least 70% knockdown.

Features of TRC lentiviral shRNA library include
- Rules-based shRNA design for efficient gene knockdown
- Already cloned into lentiviral vectors
- Amenable to in vitro and in vivo applications such as the creation of stable cell lines
- Lentiviral vector enables transduction of primary and non-dividing cell lines
- Broad coverage: 4–5 constructs per gene

TRC hairpin design
Stem: 21 base pairs
Loop: 6 bases, XhoI restriction site: CTCGAG
Flanking = 5’ CCGG overhang for AgeI
3’ TTTTTT termination for Pol III and AATT overhang for EcoRI

Vector information
The pLKO.1 HIV-based lentiviral vector (Figures 1–2, Table 1) allows for transient and stable transfection of shRNA and also the production of viral particles using lentiviral packaging systems. Stable cell lines can be selected using the puromycin selectable marker.
Table 1. Features of the pLKO.1 vector.

<table>
<thead>
<tr>
<th>Vector Element</th>
<th>Utility</th>
</tr>
</thead>
<tbody>
<tr>
<td>U6</td>
<td>Human U6 (RNA polymerase III) promoter provides high level of expression in the target cells</td>
</tr>
<tr>
<td>shRNA</td>
<td>Simple stem-loop shRNA for gene knockdown</td>
</tr>
<tr>
<td>hPGK</td>
<td>Human phosphoglycerate kinase promoter drives expression of the puromycin resistance gene</td>
</tr>
<tr>
<td>Puro&lt;sup&gt;R&lt;/sup&gt;</td>
<td>Puromycin resistance permits antibiotic-selective pressure and propagation of stable integrants</td>
</tr>
<tr>
<td>RSV/5′ LTR</td>
<td>RSV promoter/5′ long terminal repeat promotes strong lentiviral transcription in the packaging cells in the absence of Tat</td>
</tr>
<tr>
<td>3′ SIN LTR</td>
<td>3′ self-inactivating long terminal repeat for increased lentivirus safety</td>
</tr>
<tr>
<td>Ψ</td>
<td>Psi packaging sequence allows viral genome packaging using lentiviral packaging systems</td>
</tr>
<tr>
<td>RRE</td>
<td>Rev response element enhances titer by increasing packaging efficiency of full-length viral genomes</td>
</tr>
</tbody>
</table>

Antibiotic resistance

pLKO.1 contains two antibiotic resistance markers (Table 2). TRC recommends the use of carbenicillin instead of ampicillin for the growth and maintenance of pLKO.1 in bacterial cells.

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Concentration</th>
<th>Utility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbenicillin</td>
<td>100 μg/mL</td>
<td>Bacterial selection marker (outside LTRs)</td>
</tr>
<tr>
<td>Puromycin</td>
<td>Variable</td>
<td>Mammalian selection marker</td>
</tr>
</tbody>
</table>

Culturing protocols and maintenance of pLKO.1

TRC shRNA Library is constructed in the pLKO.1 vector. This vector allows for both transient and stable gene silencing through the mechanism of RNA interference (RNAi). The vector is capable of producing self-inactivating lentiviral particles when used in conjunction with an appropriate lentiviral packaging system.

In order to obtain a good yield of cells in a short period of incubation, rich medium containing carbenicillin should be used to culture pLKO.1 constructs. An incubation period of 14–20 hours at 37 °C with aeration is sufficient. It is recommended that the glycerol stocks remain frozen at −80 °C when not in use. Freeze/thaw cycles do not seem to have any detrimental effects, provided the glycerol stocks are not incubated at room temperature or higher for long periods of time.

Protocol I—Replication

Table 3. Materials and reagents for plate replication.

<table>
<thead>
<tr>
<th>Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>LB Lennox Broth (low salt)</td>
</tr>
<tr>
<td>Peptone, granulated, 2 kg – Difco</td>
</tr>
<tr>
<td>Yeast Extract, 500 g, granulated</td>
</tr>
<tr>
<td>NaCl</td>
</tr>
<tr>
<td>Glycerol</td>
</tr>
<tr>
<td>Carbenicillin</td>
</tr>
<tr>
<td>Puromycin</td>
</tr>
<tr>
<td>96-well microplates</td>
</tr>
<tr>
<td>Aluminum seals</td>
</tr>
<tr>
<td>Disposable 96 pin replicators</td>
</tr>
</tbody>
</table>

2x LB broth (low-salt) medium preparation*

<table>
<thead>
<tr>
<th>Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>LB Lennox Broth</td>
</tr>
<tr>
<td>Peptone</td>
</tr>
<tr>
<td>Yeast Extract</td>
</tr>
</tbody>
</table>

Appropriate antibiotic(s) at recommended concentration(s). Glycerol 8% for long term storage.**

*1x LB medium can be used instead of 2x LB medium.
**Glycerol can be omitted from the medium if you are culturing for plasmid preparation. If making copies of the constructs for long-term storage at −80 °C, 8% glycerol is required.
Replication of plates

Prepare target plates by dispensing ~ 160 μL of 2x LB broth supplemented with 8% glycerol and appropriate antibiotic (100 μg/mL of carbenicillin).

Prepare source plates

Carefully remove foil seals while the source plates are still frozen. This minimizes cross-contamination. Thaw the source plates with the lid on. Wipe any condensation underneath the lid with a paper wipe soaked in ethanol.

Replicate

Gently place a disposable replicator in the thawed source plate and lightly move the replicator around inside the well to mix the culture. Make sure to scrape the bottom of the plate of the well.

1. Gently remove the replicator from the source plate, carefully place in the target plate and mix in the same manner to transfer cells.
2. Dispose of the replicator.
3. Place the lids back on the source plates and target plates.
4. Repeat steps 1–4 until all plates have been replicated.
5. Return the source plates to the –80 °C freezer.
6. Place the inoculated target plates in a 37 °C incubator for 14–20 hours.

Due to the tendency of viral vectors to recombine we recommend keeping the incubation times as short as possible and avoid subculturing. Return to your glycerol stock for each plasmid preparation.

Protocol II—Plasmid preparation

Culture Conditions For Individual Plasmid Preparations

Most plasmid mini-prep kits recommend a culture volume of 1–10 mL for good yield. For shRNA constructs, 5 mL of culture can be used for one mini-prep generally producing from 5–20 μg of plasmid DNA.

1. Upon receiving your glycerol stock(s) containing the shRNA of interest, store at –80 °C until ready to begin.
2. To prepare plasmid DNA, first thaw your glycerol stock culture and pulse vortex to resuspend any E. coli that may have settled to the bottom of the tube.
3. Using a sterile loop or a pipette tip, streak the shRNA culture onto a LB agar plate containing 100 μg/mL carbenicillin. Return the glycerol stock(s) to –80 °C freezer.
4. The following day, pick 3 to 5 colonies from the agar plate and inoculate 6 mL of the 2x LB broth medium. Incubate at 37 °C for 16–20 hours with vigorous shaking (300 rpm).
5. The following day remove 1 mL of the culture and place in a sterile 2 mL sterile microcentrifuge tube. Place this tube at 4 °C until the plasmid DNA from the remaining culture has been analyzed. Pellet the remaining 5 mL culture and begin preparation of plasmid DNA. We recommend preparing ultra-pure DNA to ensure both high-purity and low endotoxin levels as required for transfection into eukaryotic cells.

If you wish to continue at a later time, cell pellets can be kept frozen at –20 °C overnight.

6. Run 3–5 μL of the plasmid DNA on a 1% agarose gel. The uncut pLKO.1 shRNA constructs run at about ~ 7–10 kb (Figure 3). Prepare an 8% glycerol stock culture using the 1 mL of culture you removed prior to plasmid preparation. This culture can be used for future plasmid preparations, but it is still recommended you streak the isolate and work from a fresh colony. Store the glycerol stocks at –80 °C.

Protocol III—Restriction digest

You may wish to perform a restriction digest with the plasmid DNA following plasmid DNA preparation. Figure 4 displays expected results for a dual restriction enzyme digestion using BamHI and NdeI restriction enzymes for quality control of pLKO.1 vectors.

Figure 3. Gel image of 1.5 mL cultures of 92 different shRNA constructs after 20 hours of incubation at 37 °C with shaking. 2x LB broth (low-salt) medium with 8% glycerol was used for culturing

Figure 4. The 1% agarose gel above contains a 10 kb ladder, undigested sample, and restriction digests of three TRC shRNA clones.

The lanes are loaded as follows:
1—Clone 1 Uncut plasmid.
2—Clone 1 Cut with BamHI. Expected to linearize at 7032 bp.
3—Clone 1 Cut with BamHI and Ndel. Band sizes of 6238 bp and 794 bp expected.
4–6—Repeat of 1–3 only with clone 2.
7–9—Repeat of 1–3 only with clone 1.
**Packaging lentivirus**

For packaging our lentiviral shRNA constructs, we recommend the Trans-Lentiviral shRNA Packaging System (Cat #TLP5912, TLP5917). The Trans-Lentiviral Packaging System allows generation of a replication-incompetent HIV-1-based lentivirus that can be used to deliver your shRNA of interest in either dividing or non-dividing mammalian cells. The Trans-Lentiviral Packaging System uses a replication-incompetent lentivirus based on the trans-lentiviral system developed by Kappes and Wu (2001). For protocols and information on packaging with our Trans-Lentiviral shRNA/ORF Packaging System, please see the product manual available on our website.

**FAQs/troubleshooting**

What clones are part of my collection? A USB drive containing the data for this collection will be shipped with each collection. This file contains the location and accession number for each construct in the collection.

Where can I find the sequence of an individual shRNA construct? If you are looking for the sequence of an individual shRNA construct, you can use the gene search. Just enter the catalog number or clone ID of the TRC clone into the search field, hit submit and then click on the query result. If you click on the “+” sign, you will find annotation of the target sequence listed in the “Targets” tab and the mature antisense sequence for each shRNA hairpin listed in the “Sequence” tab. For additional assistance, please contact Technical Support at ts.dharmacon@horizondiscovery.com.

Can I use ampicillin instead of carbenicillin? No. The TRC and the Broad Institute suggest that carbenicillin be used with the pLKO.1 vector. Constructs grown in ampicillin tend to not produce high plasmid yield.

**Reference**


**Limited use label licenses**

The Products, use and applications, are covered by pending and issued patents. Certain Label licenses govern the use of the products; these can be found here.

It is each Buyer’s responsibility to determine which intellectual property rights held by third parties may restrict the use of Products for a particular application. Please review the License Licenses governing all use of the Products.